表紙
市場調査レポート

肝臓疾患治療薬:世界市場

Liver Disease Treatments: The Global Market

発行 BCC Research 商品コード 228066
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
肝臓疾患治療薬:世界市場 Liver Disease Treatments: The Global Market
出版日: 2015年06月11日 ページ情報: 英文 141 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の肝臓疾患治療薬市場は2014年に約245億米ドルとなり、2019年まで6.7%のCAGRで推移し、2019年までに338億米ドルに近付くと予測されています。

当レポートでは、世界の肝臓疾患治療薬市場の現状と見通しについて調査分析し、肝臓疾患の種類と概要、治療に治療される主な薬剤の種類と概要、世界の主要地域における肝臓疾患の罹患率、薬剤タイプ・疾患区分・地域別の市場規模実績・予測、法規制環境・薬剤開発動向などの市場影響因子の分析、主要製造業者・供給業者の市場シェア、主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • 肝臓
  • 定義
  • 肝臓の働き
  • 肝臓疾患の一般的症状
  • 肝臓疾患
  • 中毒性肝障害
  • 病原体・寄生虫
  • 免疫障害
  • 腫瘍
  • 遺伝性肝疾患
  • その他の疾患・症状

第4章 治療の分類:疾患・製品区分別

  • ウイルス性肝疾患・肝炎
  • 抗ウイルス薬
  • 肝腫瘍・肝臓がん
  • 先天性肝障害
  • アルコール性肝臓疾患
  • 慢性肝臓疾患
  • 非アルコール性脂肪肝疾患

第5章 法規制環境

第6章 罹患率

  • 米国
  • 欧州
  • その他の地域

第7章 市場:疾患タイプ別

  • 肝炎
  • 肝細胞がん
  • 自己免疫性肝障害
  • アルコール性肝臓疾患
  • 慢性肝臓疾患
  • 非アルコール性脂肪肝疾患

第8章 パイプライン

第9章 薬剤誘発性肝臓疾患

  • 肝臓疾患を引き起こす可能性のある主な薬剤

第10章 現況・将来の展望

  • 罹患率・寿命
  • 教育不足・限られた治療選択肢
  • 研究開発
  • 団体

第11章 特許分析

第12章 企業プロファイル

  • ABBOTT LABORATORIES
  • ACHILLION PHARMACEUTICALS
  • ACTAVIS INC.
  • ALKERMES
  • ANTIPODEAN PHARMACEUTICALS
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOTEST
  • BRISTOL-MYERS SQUIBB
  • CONATUS PHARMACEUTICALS
  • ELI LILLY
  • GALECTIN THERAPEUTICS
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE
  • GRIFOLS INTERNATIONAL
  • INTERCEPT PHARMACEUTICALS
  • ISIS PHARMACEUTICALS
  • 協和発酵キリン
  • MERCK & CO.
  • NOVARTIS
  • OCERA THERAPEUTICS INC.
  • PEREGRINE
  • PFIZER
  • ROCHE
  • ROXANE LABORATORIES
  • SALIX PHARMACEUTICALS
  • SCHERING PLOUGH CORP.
  • 武田薬品工業
  • VALEANT PHARMACEUTICALS
  • VERTEX PHARMACEUTICALS INC.
  • XIAMEN AMOYTOP BIOTECH
  • ZYDUS PHARMACEUTICALS INC.

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM057C

REPORT HIGHLIGHTS

The global liver diseases therapeutics market totaled nearly $24.5 billion in 2014 and is projected to approach $33.8 billion by 2019, registering a compound annual growth rate (CAGR) of 6.7% through 2019.

This report provides:

  • An overview of the global market for liver disease treatment and related technologies.
  • Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Information regarding market sizes, market leaders, market dynamics, and various other market factors, as well as the liver disease treatment market for end users.
  • Analysis of different liver disease drugs in response to an increasing need for new and innovative drug treatments.
  • Comprehensive profiles of major players as well as the acquisitions, mergers, and alliances by these companies and global organizations.

SCOPE OF THE STUDY

The scope of this study encompasses liver disease drug markets by various types. BCC Research analyzes each market by category with its applications in different regions of the world. It also analyzes the regulatory environment, technology and market projections. Application issues include the latest trends and developments in each liver disease drug category.

ANALYST'S CREDENTIALS

Yogita Zutshi has 15 years of industry experience working in the areas of clinical research operations, medico/regulatory writing and market research in the pharmaceutical area. She has an MS in Organic Chemistry, an MS in Clinical Research and a Bachelor's in Education. She has also worked on research projects in clinical data management, and has developed training modules for the clinical and pharmacovigilance areas.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASON FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • THE LIVER
  • DEFINITIONS
  • FUNCTIONS OF LIVER
    • PRODUCTION OF BILE
    • STORAGE OF FATS, CARBOHYDRATES, PROTEINS, VITAMINS, AND MINERALS
    • REGULATION OF NECESSARY SUBSTANCES IN THE BLOOD
    • SYNTHESIS OF COAGULATING PROTEINS
    • REMOVAL OF HARMFUL SUBSTANCES
    • OTHER FUNCTIONS
  • COMMON SYMPTOMS OF LIVER DISEASE
    • FATIGUE
    • JAUNDICE
    • SWOLLEN ABDOMEN
    • EFFECTS OF HORMONAL IMBALANCE
    • STOOL ABNORMALITIES
    • POLYDYPSIA AND POLYURIA
    • HEPATIC ENCEPHALOPATHY
    • SEXUAL DYSFUNCTION
    • NON-SPECIFIC SYMPTOMS OF LIVER DISEASE
  • LIVER DISEASE
    • TABLE 1 CLASSIFICATION OF LIVER DISEASE
  • TOXIC INJURY TO THE LIVER
    • Drug-induced Liver Disease
    • Industrial and Environmental Toxins
    • Alcohol-induced
    • Postoperative Hepatic Dysfunction
  • INFECTIOUS AGENTS AND PARASITES
    • Hepatitis Virus
      • Hepatitis A
      • Hepatitis B
      • Hepatitis C
      • Hepatitis D
      • Hepatitis E
      • Neonatal Hepatitis
    • Bacterial and Other Pathogenic Agents
    • Parasites
  • IMMUNE DISORDERS
    • Autoimmune Hepatitis
    • Primary Biliary Cirrhosis
  • TUMORS
    • Primary Malignant Tumors
    • Metastatic Malignant Tumors
    • Benign Hepatic Tumors
    • Tumor-like Lesions
  • INHERITED LIVER DISEASES
    • Wilson's Disease
    • Alagille Syndrome
    • Hemochromatosis
    • Inborn Errors
    • Alpha-1 Antitrypsin Deficiency
    • Cysts
    • Galactosemia
    • Gilbert's Syndrome
    • Tyrosinemia
  • MISCELLANEOUS DISEASES AND CONDITIONS
    • Non-alcoholic Fatty Liver Disease
    • Biliary Atresia
    • Cirrhosis
    • Hepatic Encephalopathy
    • Variceal Bleeding
    • Fatty Liver Disease
    • Gallstones
    • Reye's Syndrome
    • Sarcoidosis

CHAPTER 4 - CLASSIFICATION OF THERAPIES BY DISEASE AND PRODUCTS ON THE MARKET

  • VIRUS-INDUCED LIVER DISEASE AND HEPATITIS
    • VIRAL VACCINES
      • TABLE 2: VACCINES FOR HEPATITIS A PREVENTION
      • TABLE 3: VACCINES FOR HEPATITIS B PREVENTION
  • ANTIVIRAL DRUGS
    • Nucleoside Analogs
      • TABLE 4: NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
    • Nucleotide Analogs
      • TABLE 5: NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
    • Interferon
      • TABLE 6: INTERFERONS USED TO TREAT HEPATITIS
    • Protease Inhibitors
      • TABLE 7: PROTEASE INHIBITORS USED TO TREAT HEPATITIS
    • Immunoglobulins
      • TABLE 8: IMMUNOGLOBULINS USED TO TREAT HEPATITIS
  • LIVER TUMORS AND LIVER CANCER
    • CHEMOTHERAPEUTIC DRUGS
      • TABLE 9: CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER
    • TARGETED THERAPY
      • TABLE 10: TARGETED THERAPY USED TO TREAT LIVER CANCER
  • CONGENITAL LIVER DEFECTS
    • AUTOIMMUNE LIVER DISEASES
      • TABLE 11: DRUGS USED TO TREAT WILSON'S DISEASE
    • CORTICOSTEROIDS
      • TABLE 12: CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
    • IMMUNOSUPPRESSIVE AGENTS
      • TABLE 13: IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
    • ANTIMETABOLITES
      • TABLE 14: ANTIMETABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
  • ALCOHOL-INDUCED LIVER DISEASE
    • ANABOLIC STEROIDS
      • TABLE 15: ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DISEASE
    • ALCOHOL-ABUSE DRUGS
      • TABLE 16: ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DISEASE
  • CHRONIC LIVER DISEASE
    • ANTI-REJECTION MEDICATIONS
      • TABLE 17: ANTI-REJECTION MEDICATIONS USED TO TREAT CHRONIC LIVER DISEASE
    • ANTI-INFECTIVES
      • TABLE 18: ANTI-INFECTIVES DRUGS USED TO TREAT CHRONIC LIVER DISEASE
    • ANTIFUNGAL PROPHYLAXIS
      • TABLE 19: ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
  • NON-ALCOHOLIC FATTY LIVER DISEASE
    • GALLSTONE-SOLUBILIZING AGENTS
      • TABLE 20: GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
    • OTHER DRUGS
      • TABLE 21: OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE

CHAPTER 5 - REGULATORY ASPECTS

  • TABLE 22: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
  • TABLE 23: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
  • FIGURE 1: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
  • TABLE 24: NEW DRUG APPLICATIONS, 2008-2013
  • TABLE 25: RECALLS, 2008-2014

CHAPTER 6 - PREVALENCE

  • U.S.
    • TABLE 26: U.S. PREVALENCE OF LIVER DISEASE, 2000-2020 (NUMBER)
    • TABLE 27: U.S. HEPATITIS BURDEN, 2013 (NO. OF INFECTIONS)
  • EUROPE
  • REST OF THE WORLD

CHAPTER 7 - MARKET BY DISEASE TYPE

  • TABLE 28: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
  • FIGURE 2: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, 2012-2019 ($ MILLIONS)
  • HEPATITIS
    • TABLE 29: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 3: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, 2012-2019 ($ MILLIONS)
  • HEPATOCELLULAR CARCINOMA
    • TABLE 30: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 4: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, 2012-2019 ($ MILLIONS)
  • AUTOIMMUNE LIVER DISEASES
    • TABLE 31: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
  • ALCOHOL-INDUCED LIVER DISEASE
    • TABLE 32: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
  • CHRONIC LIVER DISEASE
    • TABLE 33: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, 2012-2019 ($ MILLIONS)
  • NON-ALCOHOLIC FATTY LIVER DISEASE
    • TABLE 34: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 8: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 20120-2019 ($ MILLIONS)

CHAPTER 8 - PIPELINE

  • TABLE 35: CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
  • TABLE 36: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
  • FIGURE 9: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE

CHAPTER 9 - DRUG-INDUCED LIVER DISEASE

  • TABLE 37: DRUGS THAT CAN CAUSE LIVER DISEASE
  • MAJOR DRUGS THAT CAN CAUSE LIVER DISEASE
    • ACETAMINOPHEN (TYLENOL)
    • STATINS
    • NICOTINIC ACID (NIACIN)
    • AMIODARONE (CARDARONE)
    • NITROFURANTOIN
    • AUGMENTIN

CHAPTER 10 - CURRENT SITUATION AND FUTURE PROSPECTS

  • PREVALENCE AND LIFE EXPECTANCY
  • LACK OF EDUCATION AND LIMITED TREATMENT OPTIONS
  • RESEARCH AND DEVELOPMENT
  • LIVER ORGANIZATIONS

CHAPTER 11 - PATENT ANALYSIS

  • TABLE 38: NUMBER OF U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY, 2012-NOVEMBER, 2014
  • TABLE 39: LIST OF PATENTS ISSUED, 2012-2014
  • TABLE 40: LIST OF PATENT APPLICATIONS, 2012-2014

CHAPTER 12 - COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ACHILLION PHARMACEUTICALS
  • ACTAVIS INC.
  • ALKERMES
  • ANTIPODEAN PHARMACEUTICALS
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOTEST
  • BRISTOL-MYERS SQUIBB
  • CONATUS PHARMACEUTICALS
  • ELI LILLY
  • GALECTIN THERAPEUTICS
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE
  • GRIFOLS INTERNATIONAL
  • INTERCEPT PHARMACEUTICALS
  • ISIS PHARMACEUTICALS
  • KYOWA HAKKO KIRIN
  • MERCK & CO.
  • NOVARTIS
  • OCERA THERAPEUTICS INC.
  • PEREGRINE
  • PFIZER
  • ROCHE
  • ROXANE LABORATORIES
  • SALIX PHARMACEUTICALS
  • SCHERING PLOUGH CORP.
  • TAKEDA PHARMACEUTICAL
  • VALEANT PHARMACEUTICALS
  • VERTEX PHARMACEUTICALS INC.
  • XIAMEN AMOYTOP BIOTECH
  • ZYDUS PHARMACEUTICALS INC.

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: CLASSIFICATION OF LIVER DISEASE
    • TABLE 2: VACCINES FOR HEPATITIS A PREVENTION
    • TABLE 3: VACCINES FOR HEPATITIS B PREVENTION
    • TABLE 4: NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
    • TABLE 5: NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
    • TABLE 6: INTERFERONS USED TO TREAT HEPATITIS
    • TABLE 7: PROTEASE INHIBITORS USED TO TREAT HEPATITIS
    • TABLE 8: IMMUNOGLOBULINS USED TO TREAT HEPATITIS
    • TABLE 9: CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER
    • TABLE 10: TARGETED THERAPY USED TO TREAT LIVER CANCER
    • TABLE 11: DRUGS USED TO TREAT WILSON'S DISEASE
    • TABLE 12: CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
    • TABLE 13: IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
    • TABLE 14: ANTIMETABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
    • TABLE 15: ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DISEASE
    • TABLE 16: ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DISEASE
    • TABLE 17: ANTI-REJECTION MEDICATIONS USED TO TREAT CHRONIC LIVER DISEASE
    • TABLE 18: ANTI-INFECTIVES DRUGS USED TO TREAT CHRONIC LIVER DISEASE
    • TABLE 19: ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
    • TABLE 20: GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
    • TABLE 21: OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
    • TABLE 22: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
    • TABLE 23: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
    • TABLE 24: NEW DRUG APPLICATIONS, 2008-2013
    • TABLE 25: RECALLS, 2008-2014
    • TABLE 26: U.S. PREVALENCE OF LIVER DISEASE, 2000-2020 (NUMBER)
    • TABLE 27: U.S. HEPATITIS BURDEN, 2013 (NO. OF INFECTIONS)
    • TABLE 28: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 29: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 30: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 31: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 33: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 34: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
    • TABLE 36: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
    • TABLE 37: DRUGS THAT CAN CAUSE LIVER DISEASE
    • TABLE 38: NUMBER OF U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY, 2012-NOVEMBER, 2014
    • TABLE 39: LIST OF PATENTS ISSUED, 2012-2014
    • TABLE 40: LIST OF PATENT APPLICATIONS, 2012-2014

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 1: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
    • FIGURE 2: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, 2012-2019 ($ MILLIONS)
    • FIGURE 3: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 4: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 8: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 20120-2019 ($ MILLIONS)
    • FIGURE 9: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE 71
Back to Top